We are live on ! Find out more
ORIC icon

Oric Pharmaceuticals
ORIC

82 hedge funds and large institutions have $762M invested in Oric Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 34 increasing their positions, 20 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 20

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

19% more capital invested

Capital invested by funds: $639M → $762M (+$123M)

5% more funds holding

Funds holding: 78 → 82 (+4)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

5.86% less ownership

Funds ownership: 98.49% → 92.63% (-5.9%)

Holders
82
Holders Change
+4
Holders Change %
+5.13%
% of All Funds
1.44%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
10
Increased
34
Reduced
20
Closed
6
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
–

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$7.97M
2
EC
EcoR1 Capital
California
+$7.64M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$7.4M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.93M
5
Victory Capital Management
Victory Capital Management
Texas
+$4.9M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$12.4M
2
RCM
RA Capital Management
Massachusetts
-$10.3M
3
EC
Euclidean Capital
New York
-$4.45M
4
Millennium Management
Millennium Management
New York
-$4.1M
5
State Street
State Street
Massachusetts
-$3.89M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$123M +$7.97M +393,280 +7%
CG
2
Column Group
California
$99.7M – – –
EC
3
EcoR1 Capital
California
$72.5M +$7.64M +376,726 +12%
BlackRock
4
BlackRock
New York
$50.4M +$2.84M +140,232 +6%
O
5
OrbiMed
New York
$48.9M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$33.4M +$7.4M +365,052 +30%
Victory Capital Management
7
Victory Capital Management
Texas
$32.3M +$4.9M +241,963 +19%
ACH
8
ArrowMark Colorado Holdings
Colorado
$26.1M +$4.62M +227,809 +22%
Wells Fargo
9
Wells Fargo
California
$25.3M -$659K -32,489 -3%
State Street
10
State Street
Massachusetts
$22.2M -$3.89M -192,014 -15%
IFA
11
Invus Financial Advisors
New York
$21.1M – – –
Jennison Associates
12
Jennison Associates
New York
$20.9M +$59.4K +2,931 +0.3%
Alkeon Capital Management
13
Alkeon Capital Management
New York
$20.8M – – –
EC
14
Euclidean Capital
New York
$16.3M -$4.45M -219,541 -22%
EMFAT
15
Emerald Mutual Fund Advisers Trust
Pennsylvania
$15.5M +$3.76M +185,456 +33%
EA
16
Emerald Advisers
Pennsylvania
$15.2M +$2.5M +123,478 +20%
EAM
17
Eventide Asset Management
Massachusetts
$15.2M -$3.08M -151,976 -17%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$13.6M +$4.93M +243,343 +60%
MSKCC
19
Memorial Sloan Kettering Cancer Center
New York
$12.6M – – –
CC
20
Casdin Capital
New York
$12.6M – – –
AG
21
Artal Group
Luxembourg
$8.36M – – –
Point72 Asset Management
22
Point72 Asset Management
Connecticut
$6.98M -$12.4M -610,219 -65%
Northern Trust
23
Northern Trust
Illinois
$6.62M +$789K +38,917 +14%
Charles Schwab
24
Charles Schwab
California
$4.59M +$1.8M +88,840 +68%
BC
25
Boxer Capital
California
$4.18M – – –
1
2 3 4

ORIC Hedge Fund Activity: Q3 2021 in Review

82 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q3 2021, worth a combined $762M — up 19% from $639M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ORIC positions and 6 closed out — a net gain of 4 holders — while 34 added to existing stakes and 20 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $7.97M. The largest seller was Point72 Asset Management, cutting an estimated $12.4M.

  • 82 institutional investors held Oric Pharmaceuticals (ORIC) as of Q3 2021, up from 78 in Q2 2021.
  • Funds reported $762M of Oric Pharmaceuticals stock for Q3 2021, up 19% quarter-over-quarter.
  • 10 funds opened new Oric Pharmaceuticals positions in Q3 2021 and 6 closed out, a net change of +4 holders.
  • The largest Oric Pharmaceuticals buyer in Q3 2021 was Fidelity Investments, an estimated $7.97M added.
  • The largest Oric Pharmaceuticals seller in Q3 2021 was Point72 Asset Management, an estimated $12.4M sold.

Based on aggregated 13F filings for Q3 2021.